Aripiprazol

Agonista parcial D2 e 5-HT1A, antagonista 5-HT2A. Estabilizador dopaminérgico. Baixo risco metabólico.

1 de fev. de 20261 de

Gestação:Categoria CRisco não pode ser descartado, usar se benefício justificar

INDICAÇÕES

Adultos

10-15mg

1x/dia

Adultos

15mg

1x/dia

Adultos

2-5mg inicial

1x/dia

Inibidores CYP2D6GRAVE

Aumento aripiprazol

⛔ Reduzir dose pela metade

Indutores CYP3A4GRAVE

Redução aripiprazol

⛔ Dobrar dose

{"compativel":false,"observacao":"Dados limitados. Evitar."}

1 gene with drug interactions

Pharmacogenomics testing may help personalize dosing for this medication. Results depend on patient's genetic profile.

Data source: PharmGKB

Phenotype	Variant	Clinical Implications
Normal/Extensive Metabolizer	1/1, 1/2, 2/2	-Normal drug metabolism -Standard dosing appropriate
Poor Metabolizer	4/4, 4/5, 5/5	-Reduced drug metabolism -Increased drug levels and toxicity risk -Consider dose reduction or alternative drug
Intermediate Metabolizer	1/4, 2/4	-Moderately reduced metabolism -May need dose adjustment
Ultra-rapid Metabolizer	1/1xN, 2/2xN	-Rapid drug metabolism -Reduced drug efficacy -May need increased dose or alternative drug